Literature DB >> 25828363

Comparison of intratumoral heterogeneity of HER2 expression between primary tumor and multiple organ metastases in gastric cancer: Clinicopathological study of three autopsy cases and one resected case.

Takuya Saito1, Chihiro Kondo2, Kohei Shitara3, Yuichi Ito4, Noriko Saito5, Yuzuru Ikehara6, Yasushi Yatabe7, Keigo Yamamichi8, Hideo Tanaka1, Hayao Nakanishi9.   

Abstract

Intratumoral heterogeneity of HER2 expression in the metastatic foci of HER2-positive advanced gastric cancer remains unclear. In this study, we compared HER2 expression between primary and metastatic tumors in HER2-positive three autopsied cases and one resected case with multiple organ metastases by immunohistochemistry (IHC) and dual color in situ hybridization (DISH). All four cases judged positive (IHC3+) at the primary tumor tissues showed varying HER2 gene amplification (GA) status. One homogeneously HER2-positive autopsied case (Case 1) and one intratumorally heterogeneous positive resected case (Case 2) with high GA showed a homogeneous positive staining pattern in all the metastatic foci. One heterogeneously HER2-positive autopsied case (Case 3) with low GA showed a partially heterogeneous HER2 staining pattern in all the metastatic foci. In contrast, one heterogeneously HER2-positive autopsied case (Case 4) with equivocal GA showed a completely heterogeneous HER2 staining pattern in the metastatic foci. These results indicate that HER2-positive gastric cancers with low to high GA at the primary tumor show substantially homogeneous HER2 overexpression in the metastatic foci, whereas HER2-positive gastric cancers with equivocal GA expressed HER2 heterogeneously within the metastatic tumor, suggesting that metastatic foci of the latter HER2-positive cases would be potentially resistant to trastuzumab.
© 2015 Japanese Society of Pathology and Wiley Publishing Asia Pty Ltd.

Entities:  

Keywords:  HER2 gene amplification; drug resistance; gastric cancer; intratumoral heterogeneity; metastases; trastuzumab

Mesh:

Substances:

Year:  2015        PMID: 25828363     DOI: 10.1111/pin.12290

Source DB:  PubMed          Journal:  Pathol Int        ISSN: 1320-5463            Impact factor:   2.534


  5 in total

1.  Coupling CDH17 and CLDN18 markers for comprehensive membrane-targeted detection of human gastric cancer.

Authors:  Keisuke Matsusaka; Tetsuo Ushiku; Masayuki Urabe; Masaki Fukuyo; Hiroyuki Abe; Shumpei Ishikawa; Yasuyuki Seto; Hiroyuki Aburatani; Takao Hamakubo; Atsushi Kaneda; Masashi Fukayama
Journal:  Oncotarget       Date:  2016-09-27

2.  Prognostic implications of HER2 heterogeneity in gastric cancer.

Authors:  Shigenobu Motoshima; Koji Yonemoto; Hideki Kamei; Michi Morita; Rin Yamaguchi
Journal:  Oncotarget       Date:  2018-01-18

Review 3.  Overview on Clinical Relevance of Intra-Tumor Heterogeneity.

Authors:  Giorgio Stanta; Serena Bonin
Journal:  Front Med (Lausanne)       Date:  2018-04-06

4.  Gastric cancer biomarkers; A systems biology approach.

Authors:  Mohammad Saberi Anvar; Zarrin Minuchehr; Mohsen Shahlaei; Samira Kheitan
Journal:  Biochem Biophys Rep       Date:  2018-02-12

5.  Tumor heterogeneity and acquired drug resistance in FGFR2-fusion-positive cholangiocarcinoma through rapid research autopsy.

Authors:  Melanie A Krook; Russell Bonneville; Hui-Zi Chen; Julie W Reeser; Michele R Wing; Dorrelyn M Martin; Amy M Smith; Thuy Dao; Eric Samorodnitsky; Anoosha Paruchuri; Jharna Miya; Kaitlin R Baker; Lianbo Yu; Cynthia Timmers; Kristin Dittmar; Aharon G Freud; Patricia Allenby; Sameek Roychowdhury
Journal:  Cold Spring Harb Mol Case Stud       Date:  2019-08-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.